---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000176"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:24:42.904876+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance

## Summary
- Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
- Adjusted EBITDA surged 432% to $105.3M; company raises FY2024 revenue guidance to $1.065B-$1.125B.
- Entered new $250M term loan with OHA Agency and $100M asset-backed loan with Wells Fargo.
- Completed asset sales: RSDL product to SERB for $75M, Baltimore-Camden site for $35M, Canton warehouse for $7M.
- Received $50M from Janssen contractual dispute resolution and $30M milestone from Bavarian Nordic.

## SEC filing metadata
- accession: 0001367644-24-000176
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000176/0001367644-24-000176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000176/ebs-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000176
- JSON: https://secwatch.observer/filing/0001367644-24-000176.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.